LETICIA GONZALEZ BLANCO-rekin lankidetzan egindako argitalpenak (23)

2022

  1. Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia

    Revista de Psiquiatria y Salud Mental, Vol. 15, Núm. 1, pp. 22-28

  2. Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia

    Revista de Psiquiatria y Salud Mental, Vol. 15, Núm. 1, pp. 14-21

2021

  1. Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis

    Schizophrenia Research, Vol. 236, pp. 19-28

  2. Impact of the coronavirus outbreak on mental health in the different Spanish regions

    Actas espanolas de psiquiatria, Vol. 49, Núm. 2, pp. 64-70

  3. Real-World Functioning in Patients With Schizophrenia: Beyond Negative and Cognitive Symptoms

    Frontiers in Psychiatry, Vol. 12

  4. Spanish Validation of the MAP-SR: Two Heads Better Than One for the Assessment of Negative Symptoms of Schizophrenia

    Psicothema, Vol. 33, Núm. 3, pp. 473-480

2020

  1. COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?

    Schizophrenia Research, Vol. 223, pp. 192-198

  2. Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences

    Scientific Reports, Vol. 10, Núm. 1

  3. Early psychological impact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample

    Journal of global health, Vol. 10, Núm. 2, pp. 020505

  4. Sex-dependent grades of haematopoietic modulation in patients with major depressive episodes are associated with suicide attempts

    European Neuropsychopharmacology, Vol. 40, pp. 17-30

  5. Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene

    Schizophrenia Research

2019

  1. Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 9-16

  2. Clinical staging in severe mental disorders; bipolar disorder, depression and schizophrenia

    Revista de Psiquiatria y Salud Mental

  3. Could structural changes in the retinal layers be a new biomarker of mental disorders? A systematic review and thematic synthesis

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 116-129

  4. Early versus late stage schizophrenia. What markers make the difference?

    World Journal of Biological Psychiatry, Vol. 20, Núm. 2, pp. 159-165

  5. Factores asociados con consumo de tabaco en pacientes con depresión

    Adicciones: Revista de socidrogalcohol, Vol. 31, Núm. 4, pp. 298-308

  6. History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders

    European Addiction Research, Vol. 25, Núm. 3, pp. 111-118

  7. Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology

    Psychiatry Research, Vol. 280

2018

  1. Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia

    Psychiatry Research, Vol. 269, pp. 688-691

  2. Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia

    Revista de Psiquiatria y Salud Mental, Vol. 11, Núm. 3, pp. 130-140